文献速递哮喘

哮喘吸入性糖皮质激素给药时间的影响:一项随机三向交叉试验

The impact of dosage timing for inhaled corticosteroids in asthma: a randomised three-way crossover trial.
PubMed 文献 · Thorax · 2025-07-15

这项随机三向交叉试验纳入轻中度特应性哮喘患者,比较倍氯米松每日08:00-09:00一次400µg、15:00-16:00一次400µg及08:00-09:00和20:00-21:00各200µg每日两次三种方案。结果显示15:00-16:00给药在改善22:00 FEV1和抑制夜间血嗜酸性粒细胞方面优于其他方案,且不增加不良事件。

要点

  • 15:00-16:00单次给药改善22:00 FEV1最优。
  • 15:00-16:00给药对夜间血嗜酸性粒细胞抑制更佳。
  • 各方案均改善哮喘控制且不良事件无差异。

核心结论

  • 15:00-16:00单次给药较每日两次和08:00-09:00单次给药更好地抑制夜间肺功能下降和血嗜酸性粒细胞峰值,且不增加不良事件。

研究设计与样本

  • 随机三向交叉试验,纳入轻中度特应性哮喘患者,21例完成全部方案。

主要发现

  • 15:00-16:00给药改善22:00 FEV1中位数+160 ml(IQR +70至+270),优于08:00-09:00给药的-20 ml(IQR -80至+230)和每日两次给药的+80 ml(IQR -20至+200)。
  • 15:00-16:00给药对夜间22:00和04:00血嗜酸性粒细胞抑制优于每日两次和08:00-09:00给药。
  • 所有方案均改善哮喘控制并降低呼出气一氧化氮和血清皮质醇水平,组间无差异。

临床怎么用

  • 对轻中度特应性哮喘患者,可考虑将吸入性糖皮质激素安排在下午15:00-16:00单次给药以优化夜间肺功能控制。

局限性

  • 样本量较小,仅21例完成全部方案。
  • 需在真实世界环境中进一步验证,并确定最可能从时间治疗获益的人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Asthma demonstrates a robust daily rhythm, with airflow obstruction and airway inflammation peaking overnight. Aligning the timing of drug administration with rhythms in disease (chronotherapy) may improve therapeutic efficacy. We aimed to evaluate the impact of dosage timing for inhaled corticosteroids in asthma. METHODS: This is a randomised three-way crossover trial. Participants with mild to moderate atopic asthma were randomised to beclometasone dipropionate: (1) 400 µg once daily between 08:00 and 09:00 (ODAM); (2) 400 µg once daily between 15:00 and 16:00 (ODPM); and (3) 200 µg twice daily between 08:00 and 09:00 and between 20:00 and 21:00 (BD) for 28 days, with a 2 week washout period in between treatment periods. Six-hourly spirometry and biomarkers were measured over 24 hours following the run-in period and at the end of each treatment period. RESULTS: Of 25 participants, 21 completed all regimens. ODPM was superior in improving 22:00 FEV1 (median (IQR): +160 (+70, +270) ml) compared with ODAM (-20 (-80, +230) ml) and BD (+80 (-20, +200) ml). ODPM resulted in better overnight (22:00 and 04:00) suppression in blood eosinophil counts compared with BD and ODAM. All regimens improved asthma control and reduced fractional exhaled nitric oxide and serum cortisol levels with no difference among dosing regimens. CONCLUSION: ODPM better suppresses the nocturnal dip in lung function and peak of blood eosinophil counts compared with BD and ODAM; this was without an increase in adverse events. Future trials are warranted to validate these findings in real-life settings and to determine which population may best benefit from chronotherapy.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Wang R, Maidstone R, Singh D, et al. The impact of dosage timing for inhaled corticosteroids in asthma: a randomised three-way crossover trial. Thorax. 2025. PMID: 40234005. doi:10.1136/thorax-2024-222073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。